<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03361540</url>
  </required_header>
  <id_info>
    <org_study_id>8302-CL-0101</org_study_id>
    <nct_id>NCT03361540</nct_id>
  </id_info>
  <brief_title>ASP8302 Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Subjects</brief_title>
  <official_title>ASP8302 Phase 1 Study - A Placebo-controlled, Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety, tolerability and pharmacokinetic of
      single/multiple ascending oral doses of ASP8302 in non-elderly healthy Japanese male and
      female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by incidence of adverse events (AEs)</measure>
    <time_frame>Up to Day 6 in single ascending dose (SAD) part Up to Day 19 in MAD part</time_frame>
    <description>Adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by vital signs: Body temperature</measure>
    <time_frame>Up to Day 6 in SAD part Up to Day 19 in multiple ascending dose (MAD) part</time_frame>
    <description>To assess vital signs as a criteria of safety variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by vital signs: Blood pressure</measure>
    <time_frame>Up to Day 6 in SAD part Up to Day 19 in MAD part</time_frame>
    <description>To assess vital signs as a criteria of safety variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by vital signs: Pulse rate</measure>
    <time_frame>Up to Day 6 in SAD part Up to Day 19 in MAD part</time_frame>
    <description>To assess vital signs as a criteria of safety variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory value abnormalities and/or AEs</measure>
    <time_frame>Up to Day 6 in SAD part Up to Day 19 in MAD part</time_frame>
    <description>Number of participants with potentially clinically significant laboratory values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by cardiac troponin</measure>
    <time_frame>Up to Day 6 in SAD part Up to Day 19 in MAD part</time_frame>
    <description>To assess the cardiovascular system function as a criteria of safety variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by standard 12-lead electrocardiogram</measure>
    <time_frame>Up to Day 6 in SAD part Up to Day 19 in MAD part</time_frame>
    <description>To assess the cardiovascular system function as a criteria of safety variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameter for ASP8302: Maximum observed concentration (Cmax) in plasma</measure>
    <time_frame>Up to 72 hr after dosing in SAD part Day 1 and Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part and MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Time of the Maximum Concentration (tmax) in plasma</measure>
    <time_frame>Up to 72 hr after dosing in SAD part Day 1 and Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part and MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Area under the concentration-time curve (AUC) from the time of dosing to 24h after dosing (AUC24) in plasma</measure>
    <time_frame>Up to 72 hr after dosing in SAD part Day 1 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part and MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: AUC from the Time of Dosing Extrapolated to Time Infinity (AUCinf) in plasma</measure>
    <time_frame>Up to 72 hr after dosing in SAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: AUC from the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) in plasma</measure>
    <time_frame>Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Peak-Trough Ratio (PTR) in plasma</measure>
    <time_frame>Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Accumulation Ratio for AUC (Rac(AUC)) in plasma</measure>
    <time_frame>Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Accumulation Ratio for Cmax (Rac(Cmax)) in plasma</measure>
    <time_frame>Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: AUC from the Time of Dosing to the Last Measurable Concentration (AUClast) in plasma</measure>
    <time_frame>Up to 72 hr after dosing in SAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Time Point Prior to the Time Point Corresponding to the First Measurable (Non-zero) Concentration (tlag) in plasma</measure>
    <time_frame>Up to 72 hr after dosing in SAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Terminal Elimination Half-life (t1/2) in plasma</measure>
    <time_frame>Up to 72 hr after dosing in SAD part Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part and MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Apparent Volume of Distribution during the Terminal Elimination Phase After Single Extra-Vascular Dosing (Vz/F) in plasma</measure>
    <time_frame>Up to 72 hr after dosing in SAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Apparent Total Systemic Clearance After Single or Multiple Extra-Vascular Dosing (CL/F) in plasma</measure>
    <time_frame>Up to 72 hr after dosing in SAD part Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part and MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Concentration Immediately Prior to Dosing at Multiple Dosing (Ctrough) in plasma</measure>
    <time_frame>Up to Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Amount excreted into urine from the time of dosing to the 72 hours after dosing (Ae72) in urine</measure>
    <time_frame>Up to 72 hr after dosing in SAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Fraction excreted into urine from the time of dosing to the 72 hours after dosing (Ae72%) in urine</measure>
    <time_frame>Up to 72 hr after dosing in SAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Renal clearance (CLR) in urine</measure>
    <time_frame>Up to 72 hr after dosing in SAD part Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in SAD part and MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Amount excreted into urine over the time interval between consecutive dosing (Aetau) in urine</measure>
    <time_frame>Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ASP8302: Fraction excreted into urine over the time interval between consecutive dosing (Aetau%) in urine</measure>
    <time_frame>Day 14 in MAD part</time_frame>
    <description>To assess the PK of ASP8302 in MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) parameter for ASP8302: Pupil diameter</measure>
    <time_frame>Up to 24 hr after dosing in SAD part Up to Day 14 in MAD part</time_frame>
    <description>To assess the PD of ASP8302 in SAD part and MAD part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD parameter for ASP8302: Salivary secretion</measure>
    <time_frame>Up to 24 hr after dosing in SAD part Up to Day 14 in MAD part</time_frame>
    <description>To assess the PD of ASP8302 in SAD part and MAD part.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Single dose of ASP8302 dose-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of ASP8302.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of ASP8302 dose-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of ASP8302.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of ASP8302 dose-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of ASP8302.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of ASP8302 dose-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of ASP8302.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a single dose of Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose of ASP8302 dose-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose of ASP8302 dose-6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose of Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive once daily dosing of Placebo for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP8302</intervention_name>
    <description>ASP8302 will be administered orally.</description>
    <arm_group_label>Multiple dose of ASP8302 dose-6</arm_group_label>
    <arm_group_label>Single dose of ASP8302 dose-3</arm_group_label>
    <arm_group_label>Single dose of ASP8302 dose-4</arm_group_label>
    <arm_group_label>Multiple dose of ASP8302 dose-5</arm_group_label>
    <arm_group_label>Single dose of ASP8302 dose-1</arm_group_label>
    <arm_group_label>Single dose of ASP8302 dose-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally.</description>
    <arm_group_label>Multiple dose of Placebo</arm_group_label>
    <arm_group_label>Single dose of Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight at screening: ≥ 50.0 kg and &lt; 80.0 kg for male, ≥ 40.0 kg and &lt; 70.0 kg
             for female.

          -  Body-mass index (BMI) at screening: ≥ 17.6 kg/m2 and &lt; 26.4 kg/m2 [BMI = Body weight
             (kg) ÷ {Body height (m)2}].

        Exclusion Criteria:

          -  Subjects who participated or are scheduled to participate in any clinical trials or
             post-marketing studies within 120 days before screening test or during the screening
             test to the hospital admission (Day −2).

          -  Subjects who conducted or is scheduled to conduct any of the blood donation or blood
             drawing in designated period before Day −2

          -  Subject who received or is scheduled to receive any medications within seven days
             before the hospital admission.

          -  Any deviation from any of the normal range of blood pressure, pulse rate, body
             temperature and standard 12-lead electrocardiogram at screening or on the day of
             hospital admission (Day −1).

          -  Subject who meets any of the criteria for laboratory tests at screening or on the day
             of hospital admission (Day −2).

          -  Any deviation from the normal range of routine 12-lead electrocardiogram at screening.

          -  Subjects with a complication or history of drug allergies.

          -  Subjects who developed upper gastrointestinal symptoms within seven days before the
             hospital admission.

          -  Subjects with a complication or history of hepatic disease.

          -  Subjects with a complication or history of cardiac disease.

          -  Subjects with a complication or history of respiratory disease except for history of
             asthma in childhood.

          -  Subjects with a complication or history of gastrointestinal disease except for a
             history of appendicitis.

          -  Subjects with a history of gastrointestinal resection except for appendicitis.

          -  Subjects with a complication or history of renal disease except for a history of
             calculus.

          -  Subjects with a complication or history of endocrine disease.

          -  Subjects with a complication or history of cerebrovascular disease.

          -  Subjects with a complication or history of malignant tumor.

          -  Subjects who received ASP8302 previously.

          -  Subjects who have a habit of excessive smoking or drinking alcohol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Toshima</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>ASP8302</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

